Chapter 21: Neuromuscular Disorder & Muscle Spasm Drugs

Neuromuscular Disorder & Muscle Spasm Drugs defines Myasthenia Gravis as a chronic autoimmune condition where the immune system attacks acetylcholine receptors at the neuromuscular junction, leading to significant muscle fatigue and potential respiratory failure. The text details the use of acetylcholinesterase inhibitors, such as pyridostigmine and neostigmine, which enhance nerve impulse transmission by preventing the breakdown of acetylcholine. A critical nursing responsibility highlighted is the ability to differentiate between a myasthenic crisis, caused by insufficient medication or stress, and a cholinergic crisis, which results from a drug overdose and requires the immediate administration of atropine. The discussion then transitions to Multiple Sclerosis, an autoimmune disease characterized by the destruction of the myelin sheath in the central nervous system, creating sclerotic plaques. The chapter outlines various disease-modifying therapies, including immunomodulators like interferon beta and glatiramer acetate, as well as monoclonal antibodies like ocrelizumab, all aimed at reducing relapses and slowing the progression of physical disability. Furthermore, the material explores skeletal muscle relaxants used to treat pain and spasms from traumatic injuries or chronic conditions. These are divided into centrally acting agents like cyclobenzaprine and baclofen, which depress neuronal activity in the brain or spinal cord, and peripherally acting agents like dantrolene. Throughout the chapter, emphasis is placed on the nursing process, including monitoring respiratory status, assessing liver function, and educating patients on the importance of strict medication adherence and the dangers of combining these drugs with other central nervous system depressants like alcohol.